Program Description
As the therapeutic landscape for breast cancer rapidly evolves, oncology pharmacists must stay at the forefront of clinical updates to ensure the safe, effective, and operationally sound integration of novel agents into practice. This panel discussion will provide a comprehensive analysis of select practice-impacting abstracts from the 2025 San Antonio Breast Cancer Symposium, with a focus on HR+/HER2-negative breast cancer. Experts will evaluate the integration of novel pharmacotherapeutic approaches, including oral selective estrogen receptor degraders, AKT inhibitors, and antibody-drug conjugates. By addressing critical operational and payer-related challenges, including prior authorizations and infusion capacity, this program highlights the oncology pharmacist’s vital role in translating high-level clinical evidence into optimized, individualized patient care and in navigating complex treatment sequencing and updated guideline recommendations.
Target audience: Oncology Pharmacists
Type of activity: Application
Release date: March 6,
2026
Expiration date: March 6,
2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore recent clinical updates on novel and emerging pharmacotherapeutic approaches for the management of HR+/HER2-negative breast cancer presented at the 2025 San Antonio Breast Cancer Symposium (SABCS)
- Examine how emerging clinical evidence in HR+/HER2-negative breast cancer impacts oncology pharmacy practice, including both clinical decision-making and operational workflows
- Apply clinical insights alongside operational considerations and payer-related factors to guide the use of novel pharmacotherapeutic strategies in individualized care of patients with HR+/HER2-negative breast cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here